OUTLOOK THERAPEUTICS INC (OTLK NASDAQ) stock market data APIs
$2.0039
0.06(3%)
as of December 8, 2025
Try our APIs with
free plan!
OUTLOOK THERAPEUTICS INC Financial Data Overview
Price chart is built with
Anychart
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
Prev. Close
2.0039
Open
2.0634
High
2.0913
Low
1.9482
52 wk Range
0.79-3.39
Market Cap
91 060 K
Shares Outstanding
44 420 K
Revenue
1 505 K
EPS
-0.55
Beta
0.183
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with OUTLOOK THERAPEUTICS INC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OUTLOOK THERAPEUTICS INC data using free add-ons & libraries
Get OUTLOOK THERAPEUTICS INC Fundamental Data
OUTLOOK THERAPEUTICS INC Fundamental data includes:
- Net Revenue: 1 505 K
- EBITDA: -72 508 400
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OUTLOOK THERAPEUTICS INC News
New
After-Hours Biotech Rally: Clene Surges Ahead Of ALS Update; Werewolf, Biomea, Dyne Also Climb
(RTTNews) - Several biotech and therapeutics companies posted notable gains in after-hours trading on Tuesday, December 2, 2025, following a mix of corporate updates, investor anticipation, and recent...
Biotech Stocks Facing FDA Decision In December 2025
(RTTNews) - Every month, several health-awareness campaigns are conducted, and December, despite being a festive holiday season, is no different. Two major global and national health campaigns are rec...
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
FDA Accepts Outlook Therapeutics' Resubmitted BLA For ONS-5010 In Wet AMD, Decision Due This Month
(RTTNews) - Shares of Outlook Therapeutics (OTLK) rose nearly 15% to $1.47 in after-hours trading, following a regulatory update related to its resubmitted Biologics License Application for ONS-5010. ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
